1 August 2004 in Gastroenterology
18 August 2006 in Carcinogenesis
The transcription factor Sp1 has been implicated in cell-type-specific activation of transforming growth factor-β (TGFβ) target genes in normal epithelial cells as well as in aberrant gene activation by TGFβ in epithelial tumor cells. Here, we have examined the interaction of Sp1 with components of the Smad signaling cascade and its role in TGFβ-induced early gene expression in pancreatic cancer cells. Gene expression profiling was carried out in mithramycin-A-treated cells to identify Sp1-regulated TGFβ early response genes. We found that in pancreatic cancer cells Smad proteins and Sp1 cooperatively regulate expression of a distinct set of TGFβ target genes potentially involved in tumor progression, including MMP-11, cyclin D1 and Smad7. Mechanistically, TGFβ rapidly induces nuclear translocation of Smad proteins and subsequently stimulates Smad–Sp1 complex formation. Using the Smad7 promoter as a model for Smad-/Sp1-induced early gene activation, we demonstrated that this interaction increases Sp1 binding to GC-rich promoter boxes and results in superinduction of Sp1-mediated transcription. Moreover, inhibition of Sp1–DNA binding or transfection of Sp1-specific siRNA prevents TGFβ-induced Smad7 expression and consequently enhances Smad signaling in pancreatic cancer cells, as indicated by increased receptor-mediated phosphorylation of Smad3. We thus conclude that Sp1 strongly contributes to the aberrant transcriptional response of transformed epithelial cells to TGFβ stimulation.
2 January 2004 in Genes, Chromosomes and Cancer
1 January 2002 in Journal of Gastrointestinal Cancer
2 December 1999 in International Journal of Cancer
Activation of matrix metalloproteinase‐2 (MMP‐2) by the membrane‐type matrix metalloproteinases (MT‐MMPs) has been associated with tumor progression. In the present study, we examined the role of MMP‐2 and its activators MT1‐MMP, MT2‐MMP and MT3‐MMP in pancreatic tumor cell invasion and the development of the desmoplastic reaction characteristic of pancreatic cancer tissues. Northern blot analyses revealed that transcript levels of MT1‐MMP and MT2‐MMP, but not MT3‐MMP, were enhanced in pancreatic cancer tissues (n = 18) compared with both chronic pancreatitis (n = 9) and healthy pancreas (n = 9). A good correlation was found between MT1‐MMP and both MMP‐2 expression (p < 0.01) and activity in pancreatic cancer tissues. In addition, expression and activation of MMP‐2 were strongly associated with the extent of the desmoplastic reaction in pancreatic cancer tissues. Invasion assays showed a good correlation between MMP‐2 expression and activity and the invasive potential of pancreatic cancer cell lines. In cell lines with high levels of MMP‐2 expression and activity, the MMP inhibitor Batimastat led to significant reduction of the number of invading cells. Our results suggest that MT1‐MMP is involved in the progression of pancreatic cancer via activation of MMP‐2. MMP‐2 itself plays an important role in tumor cell invasion and appears to be associated with the development of the characteristic desmoplastic reaction in pancreatic cancer. Int. J. Cancer 85:14–20, 2000.
30 April 2000 in Gastroenterology